AbbVie (ABBV) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
AbbVie · Health Care · ref. ETF XLV · 88 calls · price $258.15
What the company does: AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines.
📈 AbbVie (ABBV) stock price
$258.15+24.2% over range
Aug 28, 25low $197.38 · high $265.97Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
81% recommend buying · 16 analysts
📊 JPI status : AbbVie has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
🎯 ABBV price target & analyst consensus — price $258
The price target · all analysts combined (16 targets)
Highest target · 1 firm of 16$303+17.4%
Median target · of 16 targets$282.5+9.4%
Lowest target · 1 firm of 16$247-4.3%
Current price$258.15
Where these 16 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
1594%
$260 ↔ $303
Below
16%
$247
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $300 (+16 %), call made on July 14, 2026, maturing on July 14, 2027 (45 d ago).
The 11 reliable analysts
$290+12 %
The 5 other firms
$278+7.7 %
How to read it: the 11 reliable firms are not filtered by optimism — 11 aim above the price, 0 below, hence their $290 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 16 ratings (last 6 months)
Strong Buy00%
Buy1381%
Hold319%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 ABBV price target all
All 21 calls, one by one, with our verdict on each firm.
→ See all 21 targets, analyst by analyst💡 The best analysts on ABBV most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in ABBV? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about AbbVie? The JPI assistant answers using our backtest data.
💰 AbbVie dividend: yield, history & growth › open the full page
2.68%annual yield
📈 Steady dividend — 12 yrs of consecutive dividend increases
That's ~$6.74 per share per year.
📈 AbbVie fundamentals: valuation, margins & growth › open the full page
P/E 74.0Net margin 9.8 %Revenue growth +10.2 %Cheap for the growth
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 20 %
2023
Rev −6%Profit −59%
2024
Rev +4%Profit −12%
2025
Rev +9%Profit −1%
🔎 Detailed analyses
🏛️ Which US Congress members hold AbbVie (ABBV)?
15 Congress members have disclosed ABBV buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Josh Gottheimer 6× · 56%Kathy Manning 5× · 43%Marjorie Greene 5× · 37%Bob Gibbs 2× · 38%Daniel Goldman 2× · 25%Richard Allen 2× · 42%Lois Frankel 2× · 45%Jared Moskowitz 2× · 25%Rob Bresnahan 2× · 31%Julia Letlow 2×
✅ Historical analyst reliability on ABBV
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Goldman Sachs ↗ | 100% | +31.9% | 4 |
| RBC Capital ↗ | 100% | +27.8% | 6 |
| Wolfe Research ↗ | 100% | +24.9% | 3 |
| UBS ↗ | 100% | +24.3% | 9 |
| Mizuho ↗ | 100% | +22.2% | 12 |
| Bernstein ↗ | 100% | +19.0% | 2 |
| Raymond James ↗ | 100% | +18.5% | 8 |
| HSBC ↗ | 100% | +18.4% | 2 |
| Citigroup ↗ | 100% | +16.7% | 14 |
| TD Cowen ↗ | 100% | +13.3% | 7 |
See the other 21 firms
| Deutsche Bank ↗ | 0% | -7.4% | 2 |
| CFRA | 0% | -5.2% | 3 |
| Societe Generale | 50% | +11.8% | 2 |
| Argus Research ↗ | 57% | -0.3% | 7 |
| B of A Securities ↗ | 57% | +4.7% | 7 |
| Jefferies ↗ | 71% | +10.9% | 14 |
| Leerink Swann | 75% | -0.1% | 4 |
| Cowen & Co. | 75% | +10.3% | 4 |
| Evercore ISI Group ↗ | 80% | +15.9% | 5 |
| JP Morgan ↗ | 80% | +19.2% | 5 |
| Credit Suisse | 80% | +20.4% | 5 |
| Morgan Stanley ↗ | 83% | +12.3% | 30 |
| BMO Capital ↗ | 87% | +13.3% | 23 |
| Barclays ↗ | 89% | +11.3% | 9 |
| Guggenheim ↗ | 90% | +13.6% | 10 |
| Truist Securities ↗ | 92% | +13.0% | 12 |
| SVB Leerink | 92% | +26.2% | 12 |
| Piper Sandler ↗ | 93% | +16.8% | 14 |
| William Blair ↗ | 100% | +10.2% | 2 |
| Wells Fargo ↗ | 100% | +11.0% | 6 |
| Cantor Fitzgerald ↗ | 100% | +11.3% | 7 |
📊 What $1,000 invested in AbbVie would be worth › open the full page
In short — $1,000 invested in AbbVie 10 years ago would be worth $4,248 today, i.e. +16%/yr on average. Best year: 2017 (+54%), worst: 2018 (-5%). Price performance, excluding dividends.
If I'd invested $1,000 in AbbVie
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,416 | +42% |
| 3 years ago | $1,557 | +56% |
| 5 years ago | $2,348 | +135% |
Return by year (AbbVie)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +10% | $1,101 (+10%) |
| 2025 | +29% | $1,416 (+42%) |
| 2024 | +15% | $1,624 (+62%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on AbbVie
Loading news…
📋 All analyst calls on ABBV
Filtered on — · ✕ show all
Piper Sandler ↗
Aug 20, 26
▲ Overweight · 🎯$303
Price at call : $264.96 — upside +14%
Today : $258.15 — upside +17%
🎯 on ABBV : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Aug 20, 27
matures : Aug 20, 27
Wells Fargo ↗
Aug 17, 26
▲ Overweight · 🎯$300
Price at call : $250.33 — upside +20%
Today : $258.15 — upside +16%
🎯 on ABBV : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Aug 17, 27
matures : Aug 17, 27
Wolfe Research ↗
Aug 13, 26
▲ Outperform · 🎯$300
Price at call : $249.46 — upside +20%
Today : $258.15 — upside +16%
🎯 on ABBV : no call matured yet · 📊 on Health : 60.9% · +4.3% (46 calls)
in progress (365j)
matures : Aug 13, 27
matures : Aug 13, 27
BNP Paribas
Aug 11, 26
■ Neutral neutral · not a buy · 🎯$247
Price at call : $248.76 — gap to target -1%
Today : $258.15 — gap to target -4%
🎯 on ABBV : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Aug 11, 27
matures : Aug 11, 27
Evercore ISI Group ↗
Aug 10, 26
▲ Outperform · 🎯$260
Price at call : $250.09 — upside +4%
Today : $258.15 — upside +1%
🎯 on ABBV : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Aug 10, 27
matures : Aug 10, 27
Guggenheim ↗
Aug 4, 26
▲ Buy · 🎯$288
Price at call : $243.8 — upside +18%
Today : $258.15 — upside +12%
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Aug 4, 27
matures : Aug 4, 27
Canaccord Genuity ↗
Aug 3, 26
▲ Buy · 🎯$290
Price at call : $243.8 — upside +19%
Today : $258.15 — upside +12%
🎯 on ABBV : no call matured yet · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Aug 3, 27
matures : Aug 3, 27
Cantor Fitzgerald ↗
Aug 3, 26
▲ Overweight · 🎯$285
Price at call : $245.1 — upside +16%
Today : $258.15 — upside +10%
🎯 on ABBV : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Aug 3, 27
matures : Aug 3, 27
See the other 80 calls, newest to oldest
▲ Overweight · 🎯$300
Price at call : $263.3 — upside +14%
Today : $258.15 — upside +16%
🎯 on ABBV : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Jul 29, 27
matures : Jul 29, 27
Canaccord Genuity ↗
Jul 22, 26
▲ Buy · 🎯$282
Price at call : $253.3 — upside +11%
Today : $258.15 — upside +9%
🎯 on ABBV : no call matured yet · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Jul 22, 27
matures : Jul 22, 27
■ Neutral neutral · not a buy · 🎯$260
Price at call : $254.39 — gap to target +2%
Today : $258.15 — gap to target +1%
🎯 on ABBV : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jul 15, 27
matures : Jul 15, 27
■ Neutral neutral · not a buy · 🎯$260
Price at call : $244.78 — gap to target +6%
Today : $258.15 — gap to target +1%
🎯 on ABBV : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
BMO Capital ↗
Jul 13, 26
▲ Outperform · 🎯$300
Price at call : $248 — upside +21%
Today : $258.15 — upside +16%
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
B of A Securities ↗
Jul 10, 26
▲ Buy · 🎯$276
Price at call : $248 — upside +11%
Today : $258.15 — upside +7%
🎯 on ABBV : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Jul 10, 27
matures : Jul 10, 27
RBC Capital ↗
Jul 10, 26
▲ Outperform · 🎯$280
Price at call : $248.08 — upside +13%
Today : $258.15 — upside +8%
🎯 on ABBV : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 10, 27
matures : Jul 10, 27
Wells Fargo ↗
Jul 10, 26
▲ Overweight · 🎯$295
Price at call : $248.08 — upside +19%
Today : $258.15 — upside +14%
🎯 on ABBV : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Jul 10, 27
matures : Jul 10, 27
Guggenheim ↗
Jul 9, 26
▲ Buy · 🎯$261
Price at call : $248.08 — upside +5%
Today : $258.15 — upside +1%
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Jul 9, 27
matures : Jul 9, 27
▲ Overweight · 🎯$280
Price at call : $249.91 — upside +12%
Today : $258.15 — upside +8%
🎯 on ABBV : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Jul 9, 27
matures : Jul 9, 27
Cantor Fitzgerald ↗
Jul 6, 26
▲ Overweight · 🎯$265
Price at call : $254.76 — upside +4%
Today : $258.15 — upside +3%
🎯 on ABBV : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Jul 6, 27
matures : Jul 6, 27
Piper Sandler ↗
Jun 23, 26
▲ Overweight · 🎯$298
Price at call : $234.89 — upside +27%
Today : $258.15 — upside +15%
🎯 on ABBV : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Jun 23, 27
matures : Jun 23, 27
Canaccord Genuity ↗
Jun 23, 26
▲ Buy · 🎯$273
Price at call : $234.89 — upside +16%
Today : $258.15 — upside +6%
🎯 on ABBV : no call matured yet · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Jun 23, 27
matures : Jun 23, 27
Evercore ISI Group ↗
May 15, 26
▲ Outperform · 🎯$235
Price at call : $209.41 — upside +12%
Today : $258.15 — upside -9%
🎯 on ABBV : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : May 15, 27
matures : May 15, 27
Piper Sandler ↗
May 14, 26
▲ Overweight · 🎯$298
Price at call : $210.39 — upside +42%
Today : $258.15 — upside +15%
🎯 on ABBV : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : May 14, 27
matures : May 14, 27
Evercore ISI Group ↗
May 4, 26
▲ Outperform · 🎯$236
Price at call : $206.11 — upside +15%
Today : $258.15 — upside -9%
🎯 on ABBV : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : May 4, 27
matures : May 4, 27
Guggenheim ↗
May 1, 26
▲ Buy · 🎯$249
Price at call : $208.16 — upside +20%
Today : $258.15 — upside -4%
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : May 1, 27
matures : May 1, 27
Canaccord Genuity ↗
May 1, 26
▲ Buy · 🎯$265
Price at call : $206.6 — upside +28%
Today : $258.15 — upside +3%
🎯 on ABBV : no call matured yet · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : May 1, 27
matures : May 1, 27
Morgan Stanley ↗
Apr 30, 26
▲ Overweight · 🎯$278
Price at call : $206.6 — upside +35%
Today : $258.15 — upside +8%
🎯 on ABBV : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Apr 30, 27
matures : Apr 30, 27
Cantor Fitzgerald ↗
Apr 30, 26
▲ Overweight · 🎯$240
Price at call : $206.6 — upside +16%
Today : $258.15 — upside -7%
🎯 on ABBV : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Apr 30, 27
matures : Apr 30, 27
Piper Sandler ↗
Apr 23, 26
▲ Overweight · 🎯$294
Price at call : $198.71 — upside +48%
Today : $258.15 — upside +14%
🎯 on ABBV : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Apr 23, 27
matures : Apr 23, 27
Canaccord Genuity ↗
Apr 21, 26
▲ Buy · 🎯$262
Price at call : $200.5 — upside +31%
Today : $258.15 — upside +1%
🎯 on ABBV : no call matured yet · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Apr 21, 27
matures : Apr 21, 27
Guggenheim ↗
Apr 10, 26
▲ Buy · 🎯$249
Price at call : $207.94 — upside +20%
Today : $258.15 — upside -4%
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Apr 10, 27
matures : Apr 10, 27
Cantor Fitzgerald ↗
Apr 8, 26
▲ Overweight · 🎯$240
Price at call : $211.59 — upside +13%
Today : $258.15 — upside -7%
🎯 on ABBV : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Apr 8, 27
matures : Apr 8, 27
RBC Capital ↗
Feb 25, 26
▲ Outperform · 🎯$260
Price at call : $224.69 — upside +16%
Today : $258.15 — upside +1%
🎯 on ABBV : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Feb 25, 27
matures : Feb 25, 27
▲ Overweight · 🎯$275
Price at call : $229.48 — upside +20%
Today : $258.15 — upside +7%
🎯 on ABBV : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 20, 27
matures : Feb 20, 27
Piper Sandler ↗
Feb 18, 26
▲ Overweight · 🎯$299
Price at call : $228.72 — upside +31%
Today : $258.15 — upside +16%
🎯 on ABBV : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Feb 18, 27
matures : Feb 18, 27
Freedom Broker
Feb 17, 26
▲ Buy · 🎯$260
Price at call : $232.86 — upside +12%
Today : $258.15 — upside +1%
🎯 on ABBV : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Feb 17, 27
matures : Feb 17, 27
■ Neutral neutral · not a buy · 🎯$230
Price at call : $223.43 — gap to target +3%
Today : $258.15 — gap to target -11%
🎯 on ABBV : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Feb 5, 27
matures : Feb 5, 27
Evercore ISI Group ↗
Feb 5, 26
▲ Outperform · 🎯$228
Price at call : $219.02 — upside +4%
Today : $258.15 — upside -12%
🎯 on ABBV : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Feb 5, 27
matures : Feb 5, 27
Morgan Stanley ↗
Feb 5, 26
▲ Overweight · 🎯$270
Price at call : $219.02 — upside +23%
Today : $258.15 — upside +5%
🎯 on ABBV : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Feb 5, 27
matures : Feb 5, 27
■ Neutral neutral · not a buy · 🎯$230
Price at call : $218.67 — gap to target +5%
Today : $258.15 — gap to target -11%
🎯 on ABBV : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jan 27, 27
matures : Jan 27, 27
Wolfe Research ↗
Jan 8, 26
■ Peer Perform neutral · not a buy
🎯 on ABBV : no call matured yet · 📊 on Health : 60.9% · +4.3% (46 calls)
in progress (365j)
matures : Jan 8, 27
matures : Jan 8, 27
Morgan Stanley ↗
Dec 12, 25
▲ Overweight · 🎯$269
Price at call : $227.45 — upside +18%
Today : $258.15 — upside +4%
🎯 on ABBV : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Dec 12, 26
matures : Dec 12, 26
▲ Buy · 🎯$265
Price at call : $225.18 — upside +18%
Today : $258.15 — upside +3%
🎯 on ABBV : no call matured yet · 📊 on Health : 53.6% · +1.4% (28 calls)
in progress (365j)
matures : Dec 10, 26
matures : Dec 10, 26
Freedom Broker
Nov 12, 25
▲ Buy · 🎯$245
Price at call : $232.29 — upside +5%
Today : $258.15 — upside -5%
🎯 on ABBV : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Nov 12, 26
matures : Nov 12, 26
■ Neutral neutral · not a buy · 🎯$220
Price at call : $218.71 — gap to target +1%
Today : $258.15 — gap to target -15%
🎯 on ABBV : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Nov 7, 26
matures : Nov 7, 26
Piper Sandler ↗
Nov 5, 25
▲ Overweight · 🎯$289
Price at call : $219.04 — upside +32%
Today : $258.15 — upside +12%
🎯 on ABBV : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Nov 5, 26
matures : Nov 5, 26
■ Neutral neutral · not a buy · 🎯$235
Price at call : $215.89 — gap to target +9%
Today : $258.15 — gap to target -9%
🎯 on ABBV : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Nov 3, 26
matures : Nov 3, 26
▲ Overweight · 🎯$260
Price at call : $215.89 — upside +20%
Today : $258.15 — upside +1%
🎯 on ABBV : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Nov 3, 26
matures : Nov 3, 26
Guggenheim ↗
Oct 20, 25
▲ Buy · 🎯$242
Price at call : $232.06 — upside +4%
Today : $258.15 — upside -6%
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Oct 20, 26
matures : Oct 20, 26
Raymond James ↗
Oct 17, 25
▲ Outperform · 🎯$250
Price at call : $232.06 — upside +8%
Today : $258.15 — upside -3%
🎯 on ABBV : no call matured yet · 📊 on Health : 46.5% · +1.6% (402 calls)
in progress (365j)
matures : Oct 17, 26
matures : Oct 17, 26
▲ Buy · 🎯$270
Price at call : $220.81 — upside +22%
Today : $258.15 — upside +5%
🎯 on ABBV : no call matured yet · 📊 on Health : 42.1% · +3.1% (19 calls)
in progress (365j)
matures : Sep 17, 26
matures : Sep 17, 26
Guggenheim ↗
Aug 1, 25
▲ Buy · 🎯$227
Price at call : $197.19 — upside +15%
Today : $258.15 — upside -12%
Expected +15% · Actual +24% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+24.3%
stock +24% · XLV +22%
matured Aug 1, 26
Guggenheim ↗
Apr 29, 25
▲ Buy · 🎯$216
Price at call : $193.51 — upside +12%
Today : $258.15 — upside -16%
Expected +12% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+5.4%
stock +5% · XLV +3%
matured Apr 29, 26
Guggenheim ↗
Apr 17, 25
▲ Buy · 🎯$214
Price at call : $170.16 — upside +26%
Today : $258.15 — upside -17%
Expected +26% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+19.7%
stock +20% · XLV +11%
matured Apr 17, 26
Guggenheim ↗
Feb 3, 25
▲ Buy · 🎯$214
Price at call : $190.14 — upside +13%
Today : $258.15 — upside -17%
Expected +13% · Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+18.7%
stock +19% · XLV +5%
matured Feb 3, 26
BMO Capital ↗
Feb 3, 25
▲ Outperform · 🎯$215
Price at call : $190.14 — upside +13%
Today : $258.15 — upside -17%
Expected +13% · Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
+18.7%
stock +19% · XLV +5%
matured Feb 3, 26
Guggenheim ↗
Jan 17, 25
▲ Buy · 🎯$212
Price at call : $172.61 — upside +23%
Today : $258.15 — upside -18%
Expected +23% · Actual +24% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+24.0%
stock +24% · XLV +9%
matured Jan 17, 26
Leerink Partners ↗
Nov 22, 24
▲ Outperform · 🎯$206
Price at call : $176.95 — upside +16%
Today : $258.15 — upside -20%
Expected +16% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 100% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
+29.7%
stock +30% · XLV +8%
matured Nov 22, 25
BMO Capital ↗
Nov 12, 24
▲ Outperform · 🎯$208
Price at call : $170.35 — upside +22%
Today : $258.15 — upside -19%
Expected +22% · Actual +36% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
+36.4%
stock +36% · XLV +4%
matured Nov 12, 25
Guggenheim ↗
Nov 6, 24
▲ Buy · 🎯$221
Price at call : $200.51 — upside +10%
Today : $258.15 — upside -14%
Expected +10% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+9.3%
stock +9% · XLV -2%
matured Nov 6, 25
Argus Research ↗
Nov 4, 24
▲ Buy
Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+7.5%
stock +7% · XLV -1%
matured Nov 4, 25
BMO Capital ↗
Oct 31, 24
▲ Outperform · 🎯$228
Price at call : $203.87 — upside +12%
Today : $258.15 — upside -12%
Expected +12% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
+7.0%
stock +7% · XLV -2%
matured Oct 31, 25
BMO Capital ↗
Oct 17, 24
▲ Outperform · 🎯$220
Price at call : $188.86 — upside +16%
Today : $258.15 — upside -15%
Expected +16% · Actual +23% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
+22.9%
stock +23% · XLV -5%
matured Oct 17, 25
▲ Buy · 🎯$225
Price at call : $193.01 — upside +17%
Today : $258.15 — upside -13%
Expected +17% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 100% (7 calls matureds) · 📊 on Health : 49% · +1.0% (96 calls)
+19.8%
stock +20% · XLV -5%
matured Oct 7, 25
BMO Capital ↗
Jul 19, 24
▲ Outperform · 🎯$214
Price at call : $173.61 — upside +23%
Today : $258.15 — upside -17%
Expected +23% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
+6.5%
stock +6% · XLV -12%
matured Jul 19, 25
BMO Capital ↗
Apr 29, 24
▲ Outperform · 🎯$180
Price at call : $162.64 — upside +11%
Today : $258.15 — upside -30%
Expected +11% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
+20.0%
stock +20% · XLV +0%
matured Apr 29, 25
Guggenheim ↗
Mar 22, 24
▲ Buy · 🎯$190
Price at call : $178.53 — upside +6%
Today : $258.15 — upside -26%
Expected +6% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+17.2%
stock +17% · XLV +1%
matured Mar 22, 25
BMO Capital ↗
Feb 5, 24
▲ Outperform · 🎯$195
Price at call : $171.26 — upside +14%
Today : $258.15 — upside -24%
Expected +14% · Actual +11% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
+10.9%
stock +11% · XLV +3%
matured Feb 4, 25
Guggenheim ↗
Apr 28, 23
▲ Buy · 🎯$171
Price at call : $153.71 — upside +11%
Today : $258.15 — upside -34%
Expected +11% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+5.1%
stock +5% · XLV +5%
matured Apr 27, 24
Guggenheim ↗
Mar 1, 23
▲ Buy · 🎯$172
Price at call : $155.27 — upside +11%
Today : $258.15 — upside -33%
Expected +11% · Actual +13% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
+13.4%
stock +13% · XLV +14%
matured Feb 29, 24
BMO Capital ↗
Feb 6, 23
▲ Outperform · 🎯$167
Price at call : $145.02 — upside +15%
Today : $258.15 — upside -35%
Expected +15% · Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
+19.5%
stock +19% · XLV +9%
matured Feb 6, 24
BMO Capital ↗
Oct 31, 22
▲ Outperform · 🎯$169
Price at call : $146.4 — upside +15%
Today : $258.15 — upside -35%
Expected +15% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
-3.6%
stock -4% · XLV -6%
matured Oct 31, 23
Argus Research ↗
Aug 24, 22
▲ Buy · 🎯$155
Price at call : $139.33 — upside +11%
Today : $258.15 — upside -40%
Expected +11% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+5.3%
stock +5% · XLV +2%
matured Aug 24, 23
BMO Capital ↗
Aug 1, 22
▲ Outperform · 🎯$170
Price at call : $140.22 — upside +21%
Today : $258.15 — upside -34%
Expected +21% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
+5.9%
stock +6% · XLV +2%
matured Aug 1, 23
BMO Capital ↗
Apr 25, 22
▲ Outperform · 🎯$174
Price at call : $156.18 — upside +11%
Today : $258.15 — upside -33%
Expected +11% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
+3.6%
stock +4% · XLV -0%
matured Apr 25, 23
▲ Outperform · 🎯$180
Price at call : $159.36 — upside +13%
Today : $258.15 — upside -30%
Expected +13% · Actual +1% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 100% (7 calls matureds) · 📊 on Health : 49% · +1.0% (96 calls)
+1.1%
stock +1% · XLV -2%
matured Apr 14, 23
BMO Capital ↗
Feb 23, 22
▲ Outperform · 🎯$161
Price at call : $146.76 — upside +10%
Today : $258.15 — upside -38%
Expected +10% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 92% (12 calls matureds) · 📊 on Health : 60.7% · +8.8% (239 calls)
+3.6%
stock +4% · XLV +3%
matured Feb 23, 23
▲ Outperform · 🎯$150
Price at call : $136.78 — upside +10%
Today : $258.15 — upside -42%
Expected +10% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 100% (7 calls matureds) · 📊 on Health : 49% · +1.0% (96 calls)
+9.1%
stock +9% · XLV +1%
matured Jan 18, 23
▲ Outperform · 🎯$130
Price at call : $119.68 — upside +9%
Today : $258.15 — upside -50%
Expected +9% · Actual +15% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 100% (7 calls matureds) · 📊 on Health : 49% · +1.0% (96 calls)
+15.2%
stock +15% · XLV -5%
matured Aug 24, 22
▲ Outperform · 🎯$120
Price at call : $106.34 — upside +13%
Today : $258.15 — upside -54%
Expected +13% · Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 100% (7 calls matureds) · 📊 on Health : 49% · +1.0% (96 calls)
+19.0%
stock +19% · XLV +22%
matured Dec 11, 21
Argus Research ↗
Jun 2, 20
▲ Buy · 🎯$115
Price at call : $90.89 — upside +27%
Today : $258.15 — upside -55%
Expected +27% · Actual +23% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+23.5%
stock +23% · XLV +19%
matured Jun 2, 21
▲ Outperform · 🎯$105
Price at call : $94.14 — upside +12%
Today : $258.15 — upside -59%
Expected +12% · Actual +13% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 100% (7 calls matureds) · 📊 on Health : 49% · +1.0% (96 calls)
+12.7%
stock +13% · XLV +11%
matured Feb 18, 21
▲ Outperform · 🎯$98
Price at call : $89.2 — upside +10%
Today : $258.15 — upside -62%
Expected +10% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 100% (7 calls matureds) · 📊 on Health : 49% · +1.0% (96 calls)
+16.0%
stock +16% · XLV +9%
matured Dec 26, 20
Argus Research ↗
Nov 6, 18
▲ Buy · 🎯$115
Price at call : $86.96 — upside +32%
Today : $258.15 — upside -55%
Expected +32% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
-5.7%
stock -6% · XLV +1%
matured Nov 6, 19
Argus Research ↗
Jun 11, 18
▲ Buy · 🎯$130
Price at call : $99.77 — upside +30%
Today : $258.15 — upside -50%
Expected +30% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
-21.6%
stock -22% · XLV +7%
matured Jun 11, 19
Argus Research ↗
Feb 2, 18
▲ Buy · 🎯$145
Price at call : $109.51 — upside +32%
Today : $258.15 — upside -44%
Expected +32% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
-28.3%
stock -28% · XLV +9%
matured Feb 2, 19
Guggenheim ↗
Oct 2, 14
▲ Buy · 🎯$70
Price at call : $56.67 — upside +24%
Today : $258.15 — upside -73%
Expected +24% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on ABBV : 90% (10 calls matureds) · 📊 on Health : 54.6% · +4.4% (97 calls)
-1.5%
stock -2% · XLV +8%
matured Oct 2, 15
Argus Research ↗
Aug 12, 13
▲ Buy
Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on ABBV : 57% (7 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+17.3%
stock +17% · XLV +19%
matured Aug 12, 14
Frequently asked questions
Should I buy AbbVie stock?
This isn't buy advice. For AbbVie, the analyst consensus is "Buy", with an average price target of $283 (+9% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (4 calls tracked on AbbVie). We show the numbers — you decide.
Is it too late to buy AbbVie? How high can it go?
The most bullish analyst target on AbbVie is $303 (+17% above today's price); the average is $283. That's the upside they see. Check how reliable those analysts have actually been on AbbVie on our site before trusting it.
Is AbbVie still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 31 analysts have a real record on AbbVie, the best hitting 100% over 4 calls. Current consensus: "Buy". Make your call on data, not noise.
Should you invest in AbbVie? The case for and against
The arguments for and against, one by one, from the numbers: why invest in ABBV (and why hesitate).
What has AbbVie's past performance been?
Historical returns and a "how much if I had invested" calculator: ABBV performance & returns.
Does AbbVie pay a dividend?
Yield, consistency and growth history of the dividend: ABBV's dividend.
What is the best month to buy ABBV?
The 12 months ranked by the stock's past returns: best & worst month to buy ABBV.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX